Graham David Y, Rimbara Emiko
Department of Medicine, Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, Texas, USA.
Department of Bacteriology II, National Institute of Infectious Diseases, Tokyo, JAPAN.
Jpn J Helicobacter Res. 2012;13(2):4-9.
Increasing antimicrobial resistance has continued to plague successful anti- eradication therapy. With rare exception, clarithromycin-containing triple therapy now provides unacceptably low treatment success. Here we discuss the factors that influence treatment outcome, how to predict outcome with new regimens, the 4-drug regimens that are currently effective in the West and their limitations, considerations about the approach to treatment failures and finally, based on the experience in the West, provide recommendations for choosing an empiric regimen in Japan. The dictum "use what works best locally" is probably the best advice for clinicians with a corollary that this dictum overrides results published by consensus conferences and advice from experts from elsewhere.
日益增加的抗菌药物耐药性持续困扰着成功的根除治疗。除了极少数例外情况,含克拉霉素的三联疗法目前的治疗成功率低得令人无法接受。在此,我们讨论影响治疗结果的因素、如何用新方案预测结果、目前在西方有效的四联疗法及其局限性、对治疗失败处理方法的考量,最后,基于西方的经验,为在日本选择经验性治疗方案提供建议。“使用当地效果最佳的药物”这一格言可能是给临床医生的最佳建议,其必然结果是这一格言优先于共识会议发表的结果和其他地方专家的建议。